Alvotech Welcomes EU Endorsement Of Higher-Strength Adalimumab
Emphasizes Global Approach As Action Still Awaited From US FDA On AVT02 Humira Rival
Alvotech has highlighted the significance to its global development strategy of the EU’s recent approval of its AVT02 higher-strength adalimumab biosimilar. However, one month on from approval, European marketing partner Stada has yet to confirm launch plans.
